Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
Studysummary In this study, a single subcutaneous dose of PTH-CBD showed similar hair regrowth to daily oral ruxolitinib in mice with alopecia, possibly through increased beta-catenin and anagen transition stimulation.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study compared the effects of a single subcutaneous injection of PTH-CBD and daily oral administration of the JAK inhibitor ruxolitinib on hair regrowth and anagen hair follicle counts in C3H/HeJ mice with alopecia areata over 8 weeks. Results showed that PTH-CBD treatment led to a significant increase in anagen hair follicles (p<0.05) and improved hair regrowth compared to ruxolitinib, despite similar immune cell infiltration. Additionally, PTH-CBD-treated mice exhibited increased beta-catenin production in hair follicles. The findings suggest that PTH-CBD can promote hair regrowth comparable to ruxolitinib, potentially by enhancing beta-catenin production and stimulating the anagen phase transition of hair follicles.
